Navigation Links
Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)
Date:5/19/2009

is is two to five years, with a five-year survival rate of approximately 20%. Patients diagnosed with IPF are usually between the ages of 40 and 70, with a median age of 63 years and the disease tends to affect slightly more men than women. There are no medicines approved by the FDA or EMEA for the treatment of IPF.

Webcast Details

InterMune will host a teleconference and webcast, with accompanying slide presentation, this evening at 9:00 p.m. EDT (6:00 p.m. PDT), in which Dr. Noble will present his oral presentation of the CAPACITY results and accompanying slides.

To access the live teleconference, dial 888-799-0528 (U.S.) or 973-200-3372 (international), conference ID# 97738057. To access the live audio webcast of the conference call, please log on to the investor relations page of the company's website at www.intermune.com. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

A replay of the webcast and teleconference will be available approximately three hours after the call. The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 97738057.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF, RECAP, an open-label extension study from CAPACITY and a resear
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting
4. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
5. Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial
6. AlphaVax Announces Promising Results in Melanoma Studies
7. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
8. BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
9. Bionovo Announces First Quarter 2009 Highlights and Financial Results
10. Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status
11. ADVENTRX Announces Results From ANX-514 Bioequivalence Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Calif. , Jan. 22, 2015  Amgen (NASDAQ: AMGN ... full year 2014 financial results on Tuesday, Jan. 27, 2015, after ... followed by a conference call with the investment community at 2 ... Robert A. Bradway , chairman and chief executive officer, and other ...
(Date:1/22/2015)... , Jan. 22, 2015 Increasing sophistication among ... consolidation of localization purchasing in 2015, says Moravia ... to a recent study by market research firm Common ... single-source solution for their translation and localization needs. "From ...
(Date:1/22/2015)... Markets ( http://www.researchandmarkets.com/research/w25xpc/allergy ) has announced the addition ... & by End User - Global Forecast to 2019" ... diagnostics market is valued at $1,228.58 million in 2014 and ... reach $2,230.72 million by 2019. Allergy diagnostics is used to ...
Breaking Medicine Technology:Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2Moravia Sees Single-Sourcing as Key Localization Trend in 2015 2Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 2Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 3
... Robbins & Myers, Inc. (NYSE: RBN ) ... second quarter ending February 28, 2010 , before the market ... is scheduled for Wednesday, March 24, 2010 , at ... Officer, and Christopher M. Hix , Vice President and Chief ...
... March 10 CVS Caremark Corporation (NYSE: CVS ) today announced that its Board of Directors has approved a quarterly dividend of $0.0875 per share on ... ... ... ...
Cached Medicine Technology:Robbins & Myers to Release Second Quarter Fiscal 2010 Financial Results 2CVS Caremark Corporation Announces Quarterly Dividend 2
(Date:1/22/2015)... its top dressmaking technologies, has been a leading dress supplier ... latest designs of wedding dresses and launching a site-wide promotion ... the fresh new products are designed for 2015, and they ... All the clothes from LunaDress follow up with the latest ...
(Date:1/22/2015)... 2015 VogueQueen is a seasoned and trusted ... many designers are thrilled to have it lead the wedding ... new collection of prom dresses for the global market. , ... strategic vision and he focuses on continuing the goal of ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 The federal court ... the U.S. District Court, Southern District of West Virginia has ... in that proceeding’s first bellwether trial. In an Order dated ... new trial after finding that C.R. Bard had not proven ...
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of Cruz ... has treated just about every type of injury that can result ... those same twenty-plus years, the team at Doctors on Liens ... best possible doctor. With the combined breadth of experience ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne wedding ... revenues in the past three years. Today, the business announces ... According to the sales manager of the company, this is ... 2015. This point can be reflected on the discounted wedding ...
Breaking Medicine News(10 mins):Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2
... of Molecular, Cellular and Developmental Biology (MCDB) and faculty ... prestigious 2006 E. B. Wilson Medal, the American ... in cell biology. ,The medal is indeed ... and function of fine, hair-like cell organelles, called cilia ...
... bath in divine dew, sunshine, herbal soup, joss-stick smoke or ... ,Sitting in a room lit with homemade joss sticks ... According to the Tibetan medical code, there are a myriad ... ,The most popular cleansing rituals include river baths, dips in ...
... suffer most under global warming. Past history gives us ... Of greatest concern are the 'large infrequent disturbances' to ... effects. In a remarkable study from the Kenyan Tsavo ... Ecology, Dr Lindsey Gillson uncovers evidence for a drought ...
... children who reportedly swallowed tiny magnets that fell off ... the Consumer Product Safety Commission has// ordered a major ... made by Mattel.,Mattel is an El Segundo-based toy manufacturer. ... around 170 complaints reporting that small magnets fell out ...
... with autism and related advocacy groups are questioning the ... a strategy for laying out// treatment resources equally across ... a series of small steps intended for helping researchers ... Media Conference, Sam Yassine, father of an autistic child ...
... of Tourism of Philippines, proposes to link-up with tour ... and check-ups with rest and recreation in// the itinerary ... ,Cynthia Carrion, the assistant secretary for Sports and Wellness ... [coordinating] with the PTAA (Philippine Travel Agencies Association) and ...
Cached Medicine News:Health News:Prestigious Wilson Award Goes To Yale Cell Biologist Joel Rosenbaum 2Health News:Prestigious Wilson Award Goes To Yale Cell Biologist Joel Rosenbaum 3Health News:Prestigious Wilson Award Goes To Yale Cell Biologist Joel Rosenbaum 4Health News:Prestigious Wilson Award Goes To Yale Cell Biologist Joel Rosenbaum 5Health News:Impact of Climate Change in Africa 2
PLX30s, 30 Watt Sealed CO2 Laser System....
... Super Pulse sealed CO2 surgical lasers offer ... the experience and support services of a ... laser experience. All settings are available at ... MD Super Pulse surgical lasers are compatible ...
Ophthalmic Nd Yag Laser with excellent quality optics for clear image and good laser delivery. Compact and light-weight for portability....
A conventional blue visibility-tinted daily-wear lens, custom made for astigmats with up to -3.00 D of cylinder requiring adds of up to +2.50 D....
Medicine Products: